Edition:
India

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

14.12USD
12:14am IST
Change (% chg)

$-0.42 (-2.89%)
Prev Close
$14.54
Open
$14.55
Day's High
$14.55
Day's Low
$13.82
Volume
32,150
Avg. Vol
79,075
52-wk High
$25.85
52-wk Low
$9.20

Latest Key Developments (Source: Significant Developments)

Rtw Investments announces private placement transaction with Rocket Pharmaceuticals Inc
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Rocket Pharmaceuticals Inc ::RTW INVESTMENTS ANNOUNCES PRIVATE PLACEMENT TRANSACTION WITH ROCKET PHARMACEUTICALS, INC..RTW INVESTMENTS ANNOUNCES PRIVATE PLACEMENT TRANSACTION WITH ROCKET PHARMACEUTICALS, INC.RTW INVESTMENTS - PURCHASE OF 967,742 SHARES OF COMMON STOCK OF ROCKET PHARMACEUTICALS AT $15.50 PER SHARE, FOR INVESTMENT AMOUNT OF $15 MILLION.  Full Article

Rocket Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 28 Nov 2018 

Nov 27 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.55 MILLION COMMON SHARES PRICED AT $15.50PER SHARE.  Full Article

Rocket Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ROCKET PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $50 MILLION OF SHARES OF ITS COMMON STOCK.ROCKET PHARMACEUTICALS - TO USE NET PROCEEDS TO FUND CONTINUED DEVELOPMENT OF PIPELINE OF GENE THERAPIES FOR RARE DISEASES.ROCKET PHARMACEUTICALS - ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND ENHANCEMENTS TO IN-HOUSE MANUFACTURING, & GENERAL CORPORATE PURPOSES.  Full Article

Rocket Pharmaceuticals Announces Preclinical Data For AAV-Based RP-A501
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS ANNOUNCES PRECLINICAL DATA FOR AAV-BASED RP-A501, THE FIRST INVESTIGATIONAL GENE THERAPY PROGRAM FOR A MONOGENIC HEART FAILURE SYNDROME.ROCKET PHARMACEUTICALS INC - THERE WERE NO TREATMENT-RELATED ADVERSE EVENTS OR DEATHS ASSOCIATED WITH RP-A501.ROCKET PHARMACEUTICALS INC - PLANS TO INITIATE A PHASE 1 DOSE-ESCALATION STUDY OF RP-A501 IN PATIENTS WITH DANON DISEASE IN FIRST HALF OF 2019.  Full Article

Rocket Pharmaceuticals And REGENXBIO Announce New License Agreement
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS AND REGENXBIO ANNOUNCE NEW LICENSE AGREEMENT FOR THE TREATMENT OF DANON DISEASE USING NAV AAV9 VECTOR.ROCKET PHARMACEUTICALS INC - INVESTIGATIONAL NEW DRUG APPLICATION EXPECTED TO BE FILED IN 2019; CLINICAL TRIAL TO FOLLOW.ROCKET PHARMACEUTICALS - REGENXBIO GRANTS CO WORLDWIDE RIGHTS TO NAV AAV9 FOR DEVELOPMENT & COMMERCIALIZATION FOR DANON DISEASE TREATMENTS.ROCKET PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, REGENXBIO WILL RECEIVE A $7 MILLION UPFRONT PAYMENT.ROCKET PHARMACEUTICALS - REGENXBIO TO GET HIGH-SINGLE TO LOW-DOUBLE DIGIT ROYALTIES ON NET SALES OF PRODUCTS WITH LICENSED INTELLECTUAL PROPERTY.  Full Article

Rocket Pharmaceuticals Qtrly Loss Per Share $0.40
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.ROCKET PHARMA - ADENO-ASSOCIATED VIRAL VECTOR PROGRAM DISCLOSURE ON TRACK FOR Q4 OF 2018, FOUR GENE THERAPY PROGRAMS EXPECTED IN CLINIC IN 2019.QTRLY LOSS PER SHARE $0.40.Q3 EARNINGS PER SHARE VIEW $-0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

Rocket Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Tuesday, 26 Jun 2018 

June 25 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.  Full Article

Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102
Saturday, 19 May 2018 

May 18 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING.ROCKET PHARMACEUTICALS - CONTINUED CLINICAL EVIDENCE DEMONSTRATES RP-L102 CAN RESTORE BONE MARROW FUNCTION OF FANCONI ANEMIA PATIENTS WITHOUT CONDITIONING.ROCKET PHARMACEUTICALS INC - ALL PATIENTS DEMONSTRATED CONTINUED IMPROVEMENT IN ENGRAFTMENT FOLLOWING ADMINISTRATION OF RP-L102 IN TRIAL.ROCKET PHARMACEUTICALS INC - NO SERIOUS DRUG-RELATED ADVERSE EVENTS HAVE BEEN OBSERVED TO DATE IN TRIAL.ROCKET PHARMACEUTICALS INC - ADDITIONAL PATIENT DATA FROM FA PROGRAM IS EXPECTED OVER NEXT 12-18 MONTHS.ROCKET PHARMACEUTICALS - ROCKET WILL ENGAGE WITH REGULATORY AUTHORITIES TO PROGRESS RP-L102 TOWARDS A POTENTIAL GLOBAL REGISTRATIONAL STUDY IN 2019.  Full Article

Rocket Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $13.25PER SHARE.  Full Article

Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals
Friday, 13 Oct 2017 

Oct 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals.Inotek Pharmaceuticals Corp - ‍additional first-in-human results from up to three programs expected in 2018​.Inotek Pharmaceuticals Corp - ‍merger is expected to close in Q1 of 2018​.  Full Article